Pharmafile Logo
Pharmafocus logo
Advanced Search
clinical_trial_4

Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan

July 22, 2016
Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab

Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …

News
biogen_austria_238

George Scangos to step down as Biogen CEO

July 21, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, George Scangos

In a surprising move, Biogen used the publishing of some promising second quarter results to announce the departure of CEO …

News

AstraZeneca’s Zavicefta meets primary endpoint in Phase III pneumonia trials

July 21, 2016
Research and Development Antibiotics, AstraZeneca, zavifecta

AstraZeneca has announced results from a Phase III trial for its recently approved antibiotic, Zavicefta (ceftazidime-avibactam), which met its primary …

News
dollars_medicines

Galenica announces $1.53 billion Replysa acquisition

July 21, 2016
Research and Development, Sales and Marketing Relypsa, Vifor pharma, galenica

Galenica has announced that it has entered into an agreement to acquire Relypsa in a deal worth $1.53 billion, which …

News
roche_dark_0

Roche beats forecasts in strong H1 results

July 21, 2016
Research and Development, Sales and Marketing 2016, Q2, Roche, h1, results

Roche has published very encouraging full results for the first half of this year, with cancer drug sales helping to …

News
test_results

Zafgen ends lead drug development, shares plummet

July 21, 2016
Research and Development zafgen

Zafgen has announced that it has dropped development of its lead drug candidate, beloranib, in order to focus on a …

News
c_lucian_milasan_ebr_jan_2015_dublin

New Irish pharma deal to save €750 million, says minister

July 20, 2016
Sales and Marketing Ireland, Irish Pharmaceutical Healthcare Association

The Irish government has struck a deal with pharmaceutical manufacturers regarding the price and supply of medicines, which is expected …

News
lab

NICE recommends PTC Therapeutics Duchenne muscular dystrophy treatment

July 20, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics

PTC Therapeutics has announced that the National Institute for Health and Care Excellence has issued final guidance recommending Translarna (ataluren) …

News
astrazeneca_crestor_rosuvastatin_40mg

AstraZeneca loses legal bid to block Crestor generics

July 20, 2016
Research and Development, Sales and Marketing AstraZeneca, Crestor, FDA, generics, legal

A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …

News
jj_sign_on_wall

J&J boosted by pharma revenue in Q2 results

July 20, 2016
Research and Development 2016, Johnson and Johnson, Q2, results

Shares at Johnson and Johnson have reached a record high of over $125 after pharma revenues helped to raise full …

News

Bristol-Myers Squibb settle $30 million California kickback lawsuit

July 20, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, california, lawsuit

Bristol-Myers Squibb (BMS) has agreed to pay $30 million to the California Department of Insurance to settle an almost decade …

News
doc_writing

FDA panel unanimously recommends approval of Valeant’s brodalumab with conditions

July 20, 2016
Research and Development, Sales and Marketing FDA, Valeant, brodalumab

Valeant has announced that the US Food and Drug Administration’s (FDA) dermatologic and ophthalmic drugs advisory committee has recommended brodalumab …

News
celgene_1_02

Celgene boosts cancer portfolio with deal worth up to $2.5 billion with Jounce Therapeutics

July 19, 2016
Research and Development, Sales and Marketing Celgene, jounce

Celgene has entered into a collaboration with Jounce Therapeutics that will see the pair jointly develop and commercialise Jounce’s lead …

News
teva_copy

Teva sells $15 billion in bonds to fund Allergan generics deal

July 19, 2016
Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics

Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …

News
opdivo_1

Opdivo to go before EU, US regulators in head and neck cancer

July 19, 2016
Manufacturing and Production, Research and Development EMA, EU, FDA, US, head and neck cancer, opdivo

Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …

News
novartis_side_building

Novartis lowers core operating profit outlook in Q2 results

July 19, 2016
Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results

Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …

News
triumeq-image-pill-bottle

New data shows superior viral suppression for Triumeq in women with HIV

July 18, 2016
Manufacturing and Production, Research and Development Triumeq, ViiV Healthcare

ViiV Healthcare has presented late-stage data showing superior efficacy for combination treatment Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir, plus other treatments, …

News
astrazeneca-sign

AstraZeneca presents positive Phase III results for lung cancer drug Tagrisso

July 18, 2016
Manufacturing and Production, Research and Development AstraZeneca, Tagrisso

AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …

News
roche__tree

Roche’s lymphoma drug fails to beat rivals in Phase III trial

July 18, 2016
Research and Development, Sales and Marketing Roche, lymphoma, phase III

Roche has announced that a Phase III trial evaluating Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma …

News
samsung

Samsung Bioepis Humira biosimilar gets accepted for EMA review

July 18, 2016
Research and Development, Sales and Marketing EMA, Humira, Samsung Bioepis, application

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application from Samsung Bioepis for their biosimilar version …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026